The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome
The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome
This study evaluated safety, tolerability and efficacy of Fluvastatin XL® -extended release
 (80 mg once daily) in patients with metabolic syndrome
Inclusion Criteria:

 -  ≥ 3 criteria for metabolic syndrome National Cholesterol Education Program Adult
 Treatment Panel III (NCEP ATP III criteria)

 -  Triglyceride (TG) < 400 mg/dl and Low Density Lipoprotein-Cholesterol (LDL-C) 100
 mg/dl to 190 mg/dl

 -  Written informed consent for participating in the study

 Exclusion Criteria:

 -  Severe renal disease or renal dysfunction

 -  Chronic liver disease or liver function impairment

 -  Inflammatory muscle dysfunction or findings of muscle problems

 -  Severe cardiac failure

 Other protocol defined inclusion exclusion criteria may apply